Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol
暂无分享,去创建一个
M. Jeong | M. Cho | C. Kim | D. Sim | S. Chae | I. Seong | J. Chae | K. Seung | H. Gwon | S. Oh | D. Kim | T. Ahn | D. Choi | S. Rha | Jin-Yong Hwang | S. Hur | J. Yoon | K. Cha | S. Joo | Jong Seon Park | H. Kim | J. Hwang
[1] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[2] Y. Ohashi,et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) , 2018, Circulation.
[3] M. Jeong,et al. Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. , 2018, Circulation journal : official journal of the Japanese Circulation Society.
[4] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[5] A. Keech,et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.
[6] Ju Han Kim,et al. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl. , 2017, The American journal of cardiology.
[7] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[8] A. Guerrero,et al. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.
[9] Ju Han Kim,et al. Multicenter Cohort Study of Acute Myocardial Infarction in Korea - Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[10] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[11] Jong Chun Park,et al. Comparing High-Intensity Versus Low-to Moderate-Intensity Statin Therapy in Korean Patients with Acute Myocardial Infarction , 2014 .
[12] P. Ridker,et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.
[13] Mary G. George,et al. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[14] Xiang Wang,et al. Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.
[15] Jeroen J. Bax,et al. Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.
[16] Takeshi Kimura,et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[17] J. Cho,et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. , 2011, Journal of the American College of Cardiology.
[18] Kyung Hoon Cho,et al. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). , 2010, The American journal of cardiology.
[19] P. Austin,et al. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.
[20] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[21] J. Liao. Safety and efficacy of statins in Asians. , 2007, The American journal of cardiology.
[22]
K. Eagle,et al.
Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein
[23] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[24] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[25] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[26] P D Cleary,et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.
[27] XiangWang,et al. Cholesterol Levels and Risk of Hemorrhagic Stroke , 2013 .
[28] G. Levine,et al. ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions , 2011 .
[29] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[30] A. Gotto,et al. The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.
[31] A. Jaffe,et al. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .